Introduction
============

Commensal gut microbiota are important for host health. They contribute to maturation of the immune system, building intestinal commensalism, resisting infectious microbes, digesting indigestible carbohydrates, and producing certain nutrients such as vitamins and short-chain fatty acids ([@B27]; [@B9]). An increasing number of reports have confirmed the link between intestinal flora disorder and disease, especially autoimmune and metabolic diseases ([@B9]; [@B1]). Although it is not clear who takes the leap and how it happens, dominant members of the intestinal microbiota are now being examined as potential probiotic candidates to assist in the treatment of disease, or become alternatives to antibiotics ([@B19]; [@B20]).

Approved probiotic products based on intestinal microbiota species mainly include lactic acid bacteria, *Bifidobacterium*, and *Escherichia coli* ([@B10]). However, there are currently no probiotic representatives of the phylum Bacteroidetes, the second-largest component of the intestinal flora. Recently, non-toxigenic *Bacteroides fragilis* (NTBF) was shown to have powerful health benefits to the host, and was recommended as a probiotic candidate ([@B30]; [@B11]; [@B6]). It is therefore likely that *B. fragilis* will be the first probiotic species from the phylum Bacteroidetes.

We previously isolated a novel *B. fragilis* strain ZY-312, and have carried out basic safety assessments to test its probiotic properties ([@B6]). Results of 16S rRNA sequence analysis, tolerance to simulated digestive fluid, safety, and adhesion to HT-29 cells suggested *B. fragilis* ZY-312 possessed desirable probiotic properties. However, these results are not sufficient to definitively conclude that ZY-312 is safe for use as a probiotic. According to the framework of evaluations for probiotics from Europe ([@B20]) and by the Food and Agriculture Organization of the United Nations and the World Health Organization ([@B7]), thorough characterization of a strain, including examination of the fatty acid profile, metabolite production, and biochemical activity, evaluation of the potential risk of transferable antibiotic resistance and genetic stability, and verification of safety in animals, especially immunodeficient animals, is an integral part of safety assessment ([@B20]). Taking advantage of whole genome sequencing technology, we carried out a thorough characterization and systematic evaluation of novel *B. fragilis* strain ZY-312 to determine whether it meets the safety criteria required for probiotics.

Materials and Methods {#s1}
=====================

Bacterial Strains and Culture Conditions
----------------------------------------

Strain ZY-312 was isolated from the feces of a healthy infant, and was previously identified using 16S rRNA gene sequence analysis ([@B6]). *B. fragilis* strain ATCC 25285 (also known as NCTC 9343) was purchased from the American Type Culture Collection (ATCC). The culture conditions and materials were as described previously for strains ZY-312 and ATCC 25285 ([@B6]). For the microbial contamination experiment, *E. coli* CBSLAM00087, *Staphylococcus aureus* (*S. aureus*) CMCC(B) 26058, *Salmonella enterica (S. enterica)* serotype Paratyphi B CBSLAM00994, *Pseudomonas aeruginosa* (*P. aeruginosa*) CBSLAM00818, *Candida albicans (C. albicans)* CMCC(F)98001, and *Clostridium sporogenes* (*C. sporogenes)* CMCC(B) 64941 were obtained from the Academy of Military Medical Science, Beijing, China. All strains were verified by PCR amplification of 16S rRNA gene using the universal primers 27 F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492 R (5′-GGTTACCTTGTTACGACTT-3′) (Lanes D--J). Amplified products were sequenced (Biomed).

Animals
-------

For acute oral toxicity studies, 6- to 8-week-old female specific pathogen-free (SPF) BALB/c mice and nude mice were procured from the Animal Experiment Center of the Academy of Military Medical Sciences, Beijing, China. The animals had free access to tap water and standard rodent diet. All of the animal experiments were performed in accordance with the approval of the Animal Ethics Committee of the Beijing Institute of Microbiology and Epidemiology, Beijing, China.

Genome Sequencing, Assembly, and Analysis
-----------------------------------------

Total DNA was extracted from all strains using a DNA extraction kit (Qiagen, USA) and the complete genome sequence of strain ZY-312 was determined using an Illumina Hiseq 2000 sequencing system ([@B31]). A genome sequencing library with an average insert size of 400 bp was generated, and raw short-read sequences were filtered using Seqprep^[1](#fn01){ref-type="fn"}^ and Sickle^[2](#fn02){ref-type="fn"}^ software. The genome was then assembled *de novo* using SOAP *de novo* software ([@B15]). Accuracy of the assembled genome sequence was evaluated by mapping all raw reads onto the scaffolds using SOAPaligner ([@B5]).

Gene prediction was carried out using Glimmer3.0 software ([@B31]). Putative antibiotic resistance genes and putative virulence factors were identified by BLAST analysis of the antibiotic resistance genes database (ARDB)^[3](#fn03){ref-type="fn"}^ ([@B14]) and the virulence factors database (VFDB)^[4](#fn04){ref-type="fn"}^ ([@B4]), respectively. A BLAST comparison was performed between the genome sequences of strain ZY-312 and *B. fragilis* strain NCTC 9343 (GenBank accession number [NC_003228](NC_003228)). A Perl script was written and the average nucleotide identity (ANI) was calculated using BLAST. A neighbor-joining phylogenetic tree was built using treebest based on the ZY-312 complete genome sequence, the complete shotgun sequences of other *B. fragilis* strains, and the complete genome sequences of *B. fragilis* strains NCTC 9343 (GenBank accession number [NC_003228](NC_003228)), YCH46 (GenBank accession number [NC_006347](NC_006347)), and *B. fragilis* 638R (GenBank accession number [NC_016776](NC_016776)).

General Characteristics of ZY-312
---------------------------------

ZY-312 was cultured on Eosin methylene blue agar for 24 h at 37°C (*E. coli* as positive control), SS agar for 24 h at 37°C (*S. enterica* serovar Paratyphi B as positive control), Columbia agar containing blood and gentamicin for 48 h at 37°C (*C. sporogenes* as positive control), mannitol sodium chloride agar for 24 h at 37°C (*S. aureus* as positive control), NAC agar for 24 h at 37°C (*P. aeruginosa* as positive control), Sabouraud dextrose agar for 72 h at 28°C (*C. albicans* as positive control), rose bengal agar for 96 h at 28°C (*C. albicans* as positive control), and agar agar for 48 h at 37°C (*S. aureus* as positive control) for excluding microbial contamination. The major fatty acids were analyzed using an HP6890 gas chromatograph (ver. A 5.01), as previously described ([@B29]). Supernatant from late-logarithmic phase ZY-312 and ATCC 25285 cultures was collected by centrifugation for 10 min at 3000 ×*g*, and then analyzed by gas chromatography-mass spectrometry. Carbon-source utilization analyses were carried out using a Biolog AN microPlate test panel (Biolog, USA). Bacterial cells were collected from logarithmic phase ZY-312 and ATCC 25285 cultures and resuspended at a concentration of 1.5 × 10^8^ colony forming units (cfu)/mL, and then inoculated into the test plate. After incubating anaerobically for 16--24 h, test results were read using a microplate reader (SpectraMax, M2), using deionized water as a negative control. To test catalase activity, 3--5 drops (about 100 μL) of 3% hydrogen peroxide (freshly prepared) were dropped onto the center of precipitated bacterial cells on microscope slides. To test gelatin liquefaction activity, bacteria were inoculated into gelatin medium, tryptone soy broth (TSB, OXIOD, UK) solidified with 15% gelatin, using a sterilized needle. Plates were incubated at 37°C for 48 h anaerobically, then placed at 4°C for 3--4 h. To determine hemolytic ability, bacteria were anaerobically cultured on tryptone soy agar (TSA, OXIOD, UK) supplemented with 5% (v/v) goat blood for 48 h at 37°C. To determine motility, bacteria were cultured on semi-solid medium (TSB solidified with 0.5% agar) at 37°C for 48 h anaerobically.

Antibiotic Resistance Testing
-----------------------------

Antibiotic resistance testing was performed using the minimum inhibitory concentration (MIC) method as described previously ([@B8]). Test antibiotics were chosen based on the antibiotic resistance genes identified in the annotated genome of ZY-312, with the following antibiotics included in the analysis: cefoxitin, ceftriaxone, cefepime, trimethoprim, clarithromycin, chloromycetin, levofloxacin, streptomycin, kanamycin, tetracycline, vancomycin, and polymyxin B (NIFDC, China). Although *bcrA* was identified in the genome, bacitracin was not used because of high toxicity, while fosmidomycin (*rosA*) is still undergoing testing and was therefore also excluded. Quinupristin/dalfopristin, the targets of the *vatB* gene product are not used in China, and there is no corresponding antibiotic for *ykkC*. ZY-312 was cultivated anaerobically at 37°C for 48 h at a concentration of 10^7^ cfu/mL with antibiotics at different concentrations. MIC was determined by measuring optical density at 600 nm (OD~600~) with a microplate reader (SpectraMax, M2).

Acute Toxicity to Normal Mice and Nude Mice
-------------------------------------------

To assess the acute toxicity of ZY-312, SPF BALB/c mice were randomly assigned into five groups (*n* = 5--8). Each group was administered with ZY-312 in a suspension containing 1 × 10^9^, 5 × 10^10^, or 5 × 10^11^ cfu/day, 0.5 mL/day culture supernatant, or 0.5 mL/day saline via oral gavage for 5 days. General condition and body weight were observed daily for 17--18 days. At the end of the experimental period, blood samples were obtained for hematological and serum biochemistry analyses. Stomach, colon, liver, and spleen were collected, weighed, and prepared for histopathological examination. Nude mice were orally administered with ZY-312 suspension at a dosage of 1 × 10^9^ cfu/day for 3 days. General condition and bodyweight were observed for 7 days.

Genetic Stability
-----------------

To explore whether genetic variation occurs in ZY-312 during *in vitro* passage, we continuously subcultured ZY-312 for 100 generations. Two parallel tubes were inoculated from an original culture of ZY-312 in TSB supplemented with 5% fetal bovine serum, and then incubated at 37°C in an anaerobic glove box (Bugbox, Ruskin) for 24 h. These initial cultures were designated A~0~ and B~0~. Subsequent passages were performed by inoculating 1% of each culture into fresh medium every 24 h, until A~100~ and B~100~ were obtained. Genetic variation was evaluated by complete genome sequencing of strains A~10~, A~25~, A~50~, and A~100~, and B~10~, B~25~, B~50~, and B~100~, and ANI was calculated for each generation. Morphological variations were observed by colony examination, Gram staining, and scanning electron microscopy (SEM) of A~100~ and B~100~, with wild-type ZY-312 used for comparison. Growth of ZY-312, A~100~, and B~100~ under anaerobic conditions was also examined over a 24-h period. Acute toxicity of A~100~ and B~100~ was detected in SPF mice at a dosage of 1 × 10^9^ cfu/day for 3 days, with general condition and bodyweight observed for 7 days.

Experimental Replicates and Statistical Methods
-----------------------------------------------

All experiments were performed at least in triplicate using independent assays, and values were expressed as the mean ± standard error. An unpaired Student's *t*-test was performed to determine statistically significant differences in the acute toxicity assays. A *p*-value of \<0.05 was considered statistically significant.

Results
=======

Morphological Characteristics
-----------------------------

Strain ZY-312 only grew under anaerobic conditions (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**), with no growth observed under aerobic conditions or in 5% CO~2~, implying it was an obligate anaerobe. Microbial contamination was excluded by culturing ZY-312 in different culture media under different conditions (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**). ZY-312 formed circular, low convex, semi-opaque colonies following anaerobic cultivation on blood agar plates (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**). Cells were Gram-negative, and shown to be rod shaped with rounded ends by scanning electrochemical microscopy (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**). This morphology matched the descriptions of *B. fragilis* in Bergey's manual ([@B12]).

General Characteristics
-----------------------

The major fatty acids of ZY-312 were C~15:0~ anteiso, C~15:0~ iso, C~16:0~, and C~16:0~ 3-OH (**Supplementary Figure [S3](#SM3){ref-type="supplementary-material"}** and **Table [1A](#T1){ref-type="table"}**). The major products in the culture supernatant of ZY-312 were lactic acid, acetic acid, succinic acid, propionic acid, and phenylacetic acid (**Table [1B](#T1){ref-type="table"}**). ZY-312 and ATCC 25285 differed in their ability to metabolize [L]{.smallcaps}-valine, salicin, [L]{.smallcaps}-alanine, [L]{.smallcaps}-alanyl-[L]{.smallcaps}-glutamine, and *N*-acetyl-[D]{.smallcaps}-glucosamine (**Table [2A](#T2){ref-type="table"}**). Both strains were positive for catalase activity, weakly positive for gelatin liquefaction, and negative for hemolytic activity and motility (**Table [2B](#T2){ref-type="table"}**). The physiological and biochemical characteristics of ZY-312 were in accordance with *B. fragilis* as described in Bergey's manual ([@B12]).

###### 

Major fatty acids (A) and major metabolites (B) of *Bacteroides fragilis* ZY-312.

  Peak name                                                    Percentage (%)   
  ----------------------- -------------- --------------------- ---------------- ---------------------
  **(A)**                                                                       
  C~15:0~ anteiso                                              32.21            
  C~15:0~ iso                                                  17.29            
  C~16:0~                                                      11.66            
  C~16:0~ 3-OH                                                 11.08            
  C~14:0~                                                      1.82             
  C~17:0~ ante 3-OH                                            1.72             
  C~18:0~                                                      1.68             
  C~15:0~                                                      1.63             
  C~18:1~ CIS 9                                                1.37             
  Unable to distinguish                                        19.55            
                                                                                
                          **ZY-312**     **ATCC 25285**                         
                          **Time (s)**   **Normalized area**   **Time (s)**     **Normalized area**
                                                                                
  **(B)**                                                                       
  Acetic acid             1514           67.24 × 10^5^         1513             27.65 × 10^5^
  Butanedioic acid        593            498.29 × 10^5^        592              107.27 × 10^5^
  propionic acid          1353           2.65 × 10^5^          1352             5.41 × 10^5^
  Phenylacetic acid       2404           1.33 × 10^5^          2403             2.06 × 10^5^
  lactic acid             424            556.78 × 10^5^        424              557.94 × 10^5^

###### 

Physiological and biochemical properties of *B. fragilis* ZY-312.

                                                     ZY-312            ATCC                                                                          ZY-312   ATCC
  -------------------------------------------------- ----------------- ----------------- ----------------------------------------------------------- -------- ------
  **(A)**                                                                                                                                                     
  Water                                              −                 −                 Dulcitol                                                    −        −
  *N*-Acetyl[-D-]{.smallcaps}galactosamine           \+                \+                [D]{.smallcaps}, [L]{.smallcaps}-α-Glycerol phosphate       −        −
  *N*-Acetyl-[D]{.smallcaps}-glucosamine             /                 \+                *N*-Acetyl-β-[D]{.smallcaps}-mannosamine                    −        −
  [D]{.smallcaps}-Fructose                           \+                \+                [L]{.smallcaps}-Fucose                                      −        −
  Adonitol                                           −                 −                 [D]{.smallcaps}-Galactose                                   \+       \+
  Amygdalin                                          \+                \+                [D]{.smallcaps}-Galacturonic acid                           −        −
  [D]{.smallcaps}-Arabitol                           −                 −                 Gentiobiose                                                 \+       \+
  Arbutin                                            \+                \+                [D]{.smallcaps}-Gluconic acid                               −        −
  [D]{.smallcaps}-Cellobiose                         \+                \+                [D]{.smallcaps}-Glucosaminic acid                           −        −
  α-Cyclodextrin                                     \+                \+                α-[D]{.smallcaps}-Glucose                                   \+       \+
  β-Cyclodextrin                                     \+                \+                Glucose-1-phosphate                                         \+       \+
  Dextrin                                            \+                \+                Glucose-6-phosphate                                         \+       \+
  Glycerol                                           −                 −                 α-Methyl-[D]{.smallcaps}-galactoside                        −        −
  i-Erythritol                                       −                 −                 β-Methyl-[D]{.smallcaps}-galactoside                        \+       \+
  m-Inositol                                         −                 −                 α-Methyl-[D]{.smallcaps}-glucoside                          −        −
  α-[D]{.smallcaps}-Lactose                          \+                \+                β-Methyl-[D]{.smallcaps}-glucoside                          −        −
  Lactulose                                          \+                \+                Palatinose                                                  \+       \+
  Maltose                                            \+                \+                [D]{.smallcaps}-Raffinose                                   \+       \+
  Maltotriose                                        \+                \+                [L]{.smallcaps}-Rhamnose                                    −        −
  [D]{.smallcaps}-Mannitol                           −                 −                 Salicin                                                     \+       −
  [D]{.smallcaps}-Mannose                            \+                \+                [D]{.smallcaps}-Sorbitol                                    −        −
  [D]{.smallcaps}-Melezitose                         −                 −                 Stachyose                                                   \+       \+
  [D]{.smallcaps}-Melibiose                          \+                \+                Sucrose                                                     \+       \+
  3-Methyl-[D]{.smallcaps}-glucose                   \+                \+                [D]{.smallcaps}-Trehalose                                   −        −
  Pyruvic acid methyl ester                          \+                \+                [D]{.smallcaps}-Lactic acid methyl ester                    −        −
  Acetic acid                                        −                 −                 [D]{.smallcaps}-Malic acid                                  −        −
  Formic acid                                        −                 −                 [L]{.smallcaps}-Malic acid                                  −        −
  Fumaric acid                                       −                 −                 Propionic acid                                              −        −
  Glyoxylic acid                                     −                 −                 Pyruvic acid                                                \+       \+
  α-Hydroxybutyric acid                              /                 /                 Turanose                                                    \+       \+
  β-Hydroxybutyric acid                              −                 −                 [D]{.smallcaps}-Saccharic acid                              −        −
  Itaconic acid                                      −                 −                 Succinamic acid                                             −        −
  α-Ketobutyric acid                                 \+                \+                Succinic acid                                               −        −
  α-Ketovaleric acid                                 \+                \+                [L]{.smallcaps}-Asparagine                                  −        −
  [D]{.smallcaps},[L]{.smallcaps}-Lactic Acid        −                 −                 m-Tartaric acid                                             −        −
  [L]{.smallcaps}-Lactic acid                        −                 −                 Urocanic acid                                               −        −
  [L]{.smallcaps}-Alaninamide                        −                 −                 [L]{.smallcaps}-Methionine                                  −        −
  [L]{.smallcaps}-Alanine                            /                 \+                [L]{.smallcaps}-Phenylalanine                               −        −
  [L]{.smallcaps}-Alanyl-[L]{.smallcaps}-glutamine   \+                /                 [L]{.smallcaps}-Serine                                      −        −
  [L]{.smallcaps}-Alanyl-[L]{.smallcaps}-histidine   /                 /                 [L]{.smallcaps}-Threonine                                   −        −
  [L]{.smallcaps}-Alanyl-[L]{.smallcaps}-threonine   \+                \+                [L]{.smallcaps}-Valine                                      /        \+
  Succinic acid monomethyl ester                     −                 −                 [L]{.smallcaps}-Valine plus [L]{.smallcaps}-aspartic acid   −        −
  [L]{.smallcaps}-Glutamic acid                      −                 −                 2′-Deoxy adenosine                                          \+       \+
  [L]{.smallcaps}-Glutamine                          −                 −                 Inosine                                                     \+       \+
  Glycyl-[L]{.smallcaps}-aspartic acid               \+                \+                Thymidine                                                   \+       \+
  Glycyl-[L]{.smallcaps}-glutamine                   −                 −                 Uridine                                                     \+       \+
  Glycyl-[L]{.smallcaps}-methionine                  −                 −                 Glycyl-[L]{.smallcaps}-proline                              −        −
  Thymidine-5′-monophosphate                         −                 −                 Uridine-5′-monophosphate                                    −        /
                                                                                                                                                              
                                                     **ZY-312**        **ATCC 25285**                                                                         
                                                                                                                                                              
  **(B)**                                                                                                                                                     
  Catalase assay                                     Positive          Positive                                                                               
  Gelatin liquefaction test                          Weakly positive   Weakly positive                                                                        
  Hemolysis test                                     Negative          Negative                                                                               
  Dynamic test                                       Negative          Negative                                                                               

Genetic Characteristics
-----------------------

The phylogenetic trees generated from the whole genome sequence of ZY-312 and other *B. fragilis* strains are shown in **Supplementary Figures [S5](#SM5){ref-type="supplementary-material"}**, **[S6](#SM6){ref-type="supplementary-material"}**. ZY-312 and ATCC 25285 had an ANI of 99.99%. In total, 33 putative virulence factors (**Table [3](#T3){ref-type="table"}**) and 11 antibiotic resistance genes (**Table [4A](#T4){ref-type="table"}**) were annotated in the ZY-312 genome based on a minimum of 40% amino acid homology. The complete genome was 4,558,494 bp in length and contained on a single chromosome, with an average GC content of 43.08%, consistent with that of *B. fragilis* (41--44%) ([@B12]). All drug-resistance genes were located on the chromosome rather than on plasmids.

###### 

Putative virulence-associated genes identified in the genome of *B. fragilis* ZY-312.

  Gene ID      VFDB_ID   Name               Function
  ------------ --------- ------------------ -------------------------------------------------------------------------------
  YDGL001582   VF0091    Alginate algI      Alginate O-acetyltransferase AlgI
  YDGL004163   VF0003    Capsule cap8E      Capsular polysaccharide synthesis enzyme Cap8E
  YDGL004164   VF0003    Capsule cap8G      Capsular polysaccharide synthesis enzyme Cap8G
  YDGL002547   VF0003    Capsule cap8M      Capsular polysaccharide synthesis enzyme Cap8M
  YDGL002015   VF0003    Capsule cap8O      Capsular polysaccharide synthesis enzyme Cap8O
  YDGL002539   VF0003    Capsule cap8O      Capsular polysaccharide synthesis enzyme Cap8O
  YDGL002014   VF0144    Capsule cps4I      UDP-*N*-acetylglucosamine-2-epimerase
  YDGL002540   VF0144    Capsule cps4I      UDP-*N*-acetylglucosamine-2-epimerase
  YDGL001235   VF0274    Capsule cpsJ       Glycosyl transferase CpsJ(V)
  YDGL004140   VF0323    Capsule fcl        Putative fucose syntheses
  YDGL002177   VF0323    Capsule glf        UDP-galactopyranose mutase
  YDGL001165   VF0072    ClpC clpC          Endopeptidase Clp
  YDGL002866   VF0072    ClpC clpC          Endopeptidase Clp
  YDGL002842   VF0074    ClpP clpP          ATP-dependent Clp protease
  YDGL001133   VF0215    Dispersin aatC     AatC ATB binding protein of ABC transporter
  YDGL003303   VF0215    Dispersin aatC     AatC ATB binding protein of ABC transporter
  YDGL003305   VF0215    Dispersin aatC     AatC ATB binding protein of ABC transporter
  YDGL003564   VF0215    Dispersin aatC     AatC ATB binding protein of ABC transporter
  YDGL003567   VF0215    Dispersin aatC     AatC ATB binding protein of ABC transporter
  YDGL004218   VF0215    Dispersin aatC     AatC ATB binding protein of ABC transporter
  YDGL002299   VF0273    Flagella fleQ      Transcriptional regulator FleQ
  YDGL002756   VF0334    HSI-I PA0073       ATP-binding component of ABC transporter
  YDGL002122   VF0159    Hsp60 htpB         Hsp60, 60K heat shock protein HtpB
  YDGL004141   VF0367    LPS gmd            GDP-mannose 4,6-dehydratase
  YDGL001251   VF0106    MgtBC mgtB         Mg^2+^transport protein
  YDGL002018   VF0153    Mip mip            Macrophage infectivity potentiator (Mip)
  YDGL003334   VF0298    MprAB mprA         MprB, sensor kinas. MprA, transcriptional factor
  YDGL003892   VF0392    *O*-Antigen ddhA   Glucose-1-phosphate cytidylyltransferase
  YDGL003891   VF0392    *O*-Antigen ddhB   CDP-glucose 4,6-dehydratase
  YDGL003902   VF0392    *O*-Antigen galE   UDP-glucose 4-epimerase
  YDGL003150   VF0319    PanC/PanD panD     panD
  YDGL003842   VF0169    SodB sodB          Superoxide dismutase
  YDGL003057   VF0101    Vi antigen tviB    Vi polysaccharide biosynthesis protein, UDP-glucose/GDP-mannose dehydrogenase

###### 

Putative antibiotic resistance genes (A) identified in the genome of *Bacteroides fragilis* ZY-312, and minimum inhibitory concentration values (B) for each of the corresponding antibiotics.

  Gene ID          Name            Drug
  ---------------- --------------- ----------------------------------
  **(A)**                          
  YDGL002306       BcrA            Bacitracin
  YDGL000449       BL2e_cepa       Cephalosporin
  YDGL000258       dfrA22          Trimethoprim
  YDGL003477       MefA            Macrolide
  YDGL001150       MexF            Chloramphenicol, Fluoroquinolone
  YDGL000604       MexY            Aminoglycoside, Glycylcycline
  YDGL003440       RosA            Fosmidomycin
  YDGL003171       tet37           Tetracycline
  YDGL003704       VanRA           Vancomycin, Teicoplanin
  YDGL003646       VatB            Streptogramin_A
  YDGL000090       YkkC            na_antimicrobials
                                   
  **Antibiotic**   **ZY-312**      **ATCC 25285**
                                   
  **(B)**                          
  Cefoxitin        MIC = 2.0       MIC = 1.5
  Ceftriaxone      MIC \< 64       MIC \< 64
  Cefepime         MIC \> 32       MIC \> 32
  Trimethoprim     MIC \< 16       MIC \< 16
  Clarithromycin   MIC \< 8        MIC \< 8
  Chloromycetin    MIC \< 32       MIC \< 32
  Levofloxacin     MIC \< 8        MIC \< 8
  Streptomycin     MIC \> 1200     MIC \> 1200
  Kanamycin        MIC \> 50       MIC \> 50
  Tetracycline     MIC \< 16       MIC \< 16
  Vancomycin       4 \< MIC \< 8   4 \< MIC \< 8
  Polymyxin B      MIC \> 8        MIC \> 8

Bacitracin was eliminated because of high toxicity. Fosmidomycin is still being researched and was therefore excluded. Quinupristin/dalfopristin are not available in China and were also excluded. No corresponding antibiotic exists for the ykkC gene product.

Putative Virulence Factors
--------------------------

Through BLAST analysis of the VFDB, a total of 33 virulence factor homologs were identified in the genome of ZY-312 (**Table [3](#T3){ref-type="table"}**). Most of these putative virulence genes encoded proteins involved in cellular structure or physiological activities, and none had previously been reported as being related to the pathogenesis of *B. fragilis*. Notably, *bft* was not present in the genome of ZY-312, indicating that it is a non-toxigenic strain.

Antibiotic Resistance
---------------------

Antibiotic resistance tests were performed based on the antibiotic resistance genes identified in the genome of YZ-312 (**Table [4A](#T4){ref-type="table"}**), and results are summarized in **Table [4B](#T4){ref-type="table"}**. Based on guidelines for antibiotic resistance breakpoints ([@B25]; [@B21]), ZY-312 showed resistance to cefepime, kanamycin, and streptomycin, but was susceptible to ceftriaxone, trimethoprim, clarithromycin, chloramphenicol, tetracycline, and levofloxacin. Without available guidelines for *B. fragilis*, resistance of ZY-312 to vancomycin and polymyxin B could not be confirmed; however, we observed that 4--8 μg/mL vancomycin and \>8 μg/mL polymyxin B were sufficient to inhibit ZY-312 growth *in vitro*.

ZY-312 Is Non-pathogenic in Both Normal and Immune-Deficient Mice
-----------------------------------------------------------------

To confirm the *in vivo* safety of ZY-312, acute toxicity experiments were performed in both normal SPF BALB/c mice and nude mice. Lacking a thymus and an immune response, nude mice are an ideal animal model for evaluating probiotic safety. No death was observed in the BALB/c mice during the toxicity experiments, no treatment-related toxicity was observed, and no significant difference in body weight was noted between low, medium (**Supplementary Figure [S4](#SM4){ref-type="supplementary-material"}**), and high (**Figure [1A-1](#F1){ref-type="fig"}**) dose treatment groups and the control group, respectively. Similarly, no difference was found between the culture supernatant-treated group and the control group (**Figure [1A-2](#F1){ref-type="fig"}**). In addition, there was no obvious histopathological damage in the stomach, colon, liver, or spleen of BALB/c mice from the high dosage group (**Figure [1B](#F1){ref-type="fig"}**). There were also no significant differences in blood routine index or hepatorenal function between the high dose and control groups (data not shown). For the immune-deficient mouse toxicity experiments, ZY-312 again had no deleterious effects on body weight (**Figure [1A-3](#F1){ref-type="fig"}**).

![**ZY-312 is non-pathogenic in mice. (A)** Changes in body weight (%) per day were observed for the experimental and control groups. **(A-1)** Specific pathogen-free (SPF) BALB/c normal mice (*n* = 8) were treated with 5 × 10^11^ colony forming units (cfu)/day ZY-312 for 5 days and observed for 18 days. A control group was treated with saline. **(A-2)** SPF normal mice (*n* = 16) were treated with culture supernatant (0.5 mL/day) for 5 days and observed for 17 days. Tryptic soy broth was used for the control group. **(A-3)** Nude mice (*n* = 5) were treated with ZY-312 at a concentration of 1 × 10^9^ cfu/day for 3 days and observed for 7 days. The control group were treated with saline. **(B)** Light micrograph images of the stomach, colon, liver, and spleen from mice belonging to the high dosage group (upper) and control group (lower). No significant lesions were observed (mean ± SE; NS, not significant, *t*-test).](fmicb-08-00435-g001){#F1}

ZY-312 Is Genetically and Phenotypically Stable
-----------------------------------------------

To explore whether ZY-312 undergoes major genomic rearrangements during passage, the stability of ZY-312 was examined after 100 generations *in vitro*. A~100~ and B~100~ were morphologically identical to the original ZY-312 strain (**Figure [2A](#F2){ref-type="fig"}**) based on visual inspection, optical microscopy, and SEM. The growth characteristics of A~100~ and B~100~ (**Figure [2B](#F2){ref-type="fig"}**) were not significantly different from those of ZY-312. Furthermore, following oral administration of A~100~ or B~100~ at a dose of 1 × 10^9^ cfu/day for 3 days, mice did not show any clinical symptoms or weight loss during the observation period (**Figure [2C](#F2){ref-type="fig"}**). The calculated ANI values from each generation were at least 99.98% (**Figure [2D](#F2){ref-type="fig"}**).

![**ZY-312 is genetically stable. (A)** Gram-stained ZY-312, A~100~, and B~100~ cells following anaerobic culture on tryptic soy agar (5% sheep blood) for 48 h at 37°C. Observation were made using a light microscope (4000×) and a scanning electron microscope (30000×). **(B)** Growth curves of ZY-312, A~100~, and B~100~ cultured anaerobically for 24 h. **(C)** SPF BALB/c normal mice (*n* = 8) were treated with A~100~ or B~100~ at a concentration of 1 × 10^9^ cfu/day for 3 days and observed for 7 days. A control group was treated with saline. **(D)** Average nucleotide identities were calculated between each generation.](fmicb-08-00435-g002){#F2}

Discussion
==========

According the recent reports, non-toxic *B. fragilis* now is regarded as a commensal constituent with potential as a probiotic candidate ([@B11]), because of powerful immunoregulatory benefits and health-promoting effects it owns. Although *B. fragilis* makes up a very small part of the human intestinal flora, it plays a unique role in the maturation of the host immune system ([@B17]; [@B30]). Mono-colonization of mice with *B. fragilis* was sufficient to correct systemic immune defects in germ-free mice by stimulating maturation of splenic CD4^+^ T cells ([@B17]) and rebalancing the Th1/Th2 response. Furthermore, *B. fragilis* can direct an anti-inflammatory response, conferring protection in experimental mouse models of colitis ([@B18]; [@B24]) and of autoimmune encephalomyelitis ([@B22]). Those observed effects were absent in mice treated with a *B. fragilis* PSA-deficient mutant strain. PSA is a dominant member of capsular polysaccharide complex (CPC) at the surface of *B. fragilis*, and contains a zwitterionic motif. *B. fragilis* is associated with clinical anaerobic infection and the CPC, especially PSA plays a key role in arising those diseases ([@B13]; [@B16]). Nevertheless, the role of PSA plays in intra-abdominal abscess probably is beneficial rather than harmful, since the inflammation aroused by PSA helps limit the spread of other gut bacteria and prevent more serious infection ([@B16]; [@B6]). Instead of being recognized as virulence factor, recently, PSA has been reconsidered as a symbiosis factor with health-promoting effect ([@B18]).

Therefore, under overall considerations about the pros and cons, we believe non-toxic *B. fragilis* is a good choice for probiotic candidate and we decided to isolate a new strain of *B. fragilis* named ZY-312 ([@B6]) and explore its safety whether satisfy the criteria required for probiotic bacteria. Although the health benefits of *B. fragilis* are generally recognized, much work still needs to be done to obtain certification of this species as a probiotic. Probiotics are defined as non-pathogenic live microorganisms that confer health benefits to the host when administered in adequate amounts ([@B7]). As living microorganisms with the potential for infection or *in situ* toxin production, probiotics should fulfill health and safety claims before entering the market. Safety assessment is the chief task for certifying a probiotic, as any adverse effects should be predicted in advance. Accordingly ([@B7]; [@B20]), correct identification, sufficient characterization, and evaluation of potential risk and probiotic properties are integral for evaluation of a new probiotic.

Previously, we demonstrated that novel strain ZY-312, isolated from the feces of a healthy breast-fed infant, possessed similar morphological and growth characteristics to typical *B. fragilis* strains, as well as exhibiting desirable probiotic properties, including tolerance to air, simulated gastric fluid (pH 3.0), simulated intestinal fluid and ox bile (pH 6.8), adhesion, and *in vitro* safety in colon cells ([@B6]). Based on these results, we carried out a more thorough characterization and systemic evaluation of ZY-312 in the current study. As recommended ([@B7]), phenotypic testing, fatty acid analysis, metabolite production, biochemical activity, and *in vivo* toxicity testing, in combination with genetic analysis, taxonomic identification, and putative virulence and antibiotic resistance gene identification analysis, were performed to determine whether ZY-312 is safe for use as a probiotic. The major fatty acids and metabolic products of ZY-312 closely resemble descriptions of *B. fragilis* in Bergey's manual, as do the results of biochemical activity testing. Our previous work showed that the 16S rRNA sequence of ZY-312 was 99% identical to that of *B. fragilis* strain ATCC 28285. However, 16S rRNA sequence analysis has potential drawbacks for separating closely related species because of low taxonomic resolution. Whole genome sequencing identifies taxa with higher taxonomic resolution, and provides more information about gene function, such as putative virulence factors and antibiotic resistance genes ([@B23]; [@B20]). Taking advantage of whole genome sequencing technology in the current study, we showed that ZY-312 and ATCC 25285 shared 99.99% ANI, and were derived from the same origin (**Supplementary Figure [S5](#SM5){ref-type="supplementary-material"}**), consistent with previous results. Furthermore, a total of 33 putative virulence factors and 11 antibiotic resistance genes were annotated in the genome of ZY-312 through comparative analysis with the VFDB and the ARDB, respectively. The putative virulence factors consisted of structural proteins and proteins with physiological activity, and none had previously been reported in association with the pathogenesis of *B. fragilis*. Because of the absence of *bft*, ZY-312 was identified as a NTBF strain.

There are many reports claiming probiotic safety based on an assessed lack of infectivity in normal animals ([@B2]; [@B28]). However, confidence would be increased if assessment could be performed in immunodeficient animals ([@B7]). Therefore, we examined the safety of ZY-312 in both normal and immunodeficient mice. The SPF normal mice treated with high doses or supernatant of ZY-312 did not display any significant strain-related toxigenic symptoms, based on the assessment of body weight changes, histopathological examination, blood routine index, and hepatorenal function. Notably, ZY-312 also proved safe in nude mice (**Figure [1A-3](#F1){ref-type="fig"}**).

The FAO/WHO recommends that probiotic strains should be fully characterized, including determination of antibiotic resistance patterns, and should have no risk of transferring antibiotic resistance ([@B7]). Theoretically, consumption of probiotics with transferrable antibiotic resistance genes might lead to refractory infections if multiple antibiotic resistance genes are transferred to a pathogen ([@B3]; [@B26]). We demonstrated that there is no risk of ZY-312 spreading antibiotic resistance because all identified drug-resistance genes (**Table [4A](#T4){ref-type="table"}**) were located in the chromosome rather than on a plasmid. Moreover, we verified the antibiotic resistance phenotype of ZY-312, and discovered that it is resistant to cefepime, kanamycin, and streptomycin, but susceptible to ceftriaxone, trimethoprim, clarithromycin, chloramphenicol, tetracycline, and levofloxacin. The MICs of vancomycin and polymyxin B for ZY-312 were also identified (**Table [4B](#T4){ref-type="table"}**). The inconsistencies between genotype and observed phenotype might stem from the fact that putative antibiotic resistance genes were annotated based on 40% amino acid homology, meaning that some genes were incorrectly identified in the genome of ZY-312, and are likely not present.

As potential genetic variation might lead to unpredictable risk, genetic stability should also be confirmed prior to starting large-scale production of ZY-312-based probiotics ([@B26]). We confirmed that following *in vitro* passage of 100 generations from the original strain of ZY-312, there was no significant difference between A~100~, B~100~, and the parental strain with respect to morphological characteristics and growth features. No *in vivo* toxicity was observed for A~100~ or B~100~, and the ANI between each generation was at least 99.98%, demonstrating that ZY-312 has a high degree of genetic stability.

Conclusion
==========

We confirmed that ZY-312 is a NTBF strain, without potential virulence factors or risk of spreading antibiotic resistance genes. As well as having desirable probiotic properties ([@B6]), ZY-312 has a high degree of genetic stability and is non-pathogenic, even to immune-deficient mice. Therefore, ZY-312 is most likely safe for use in future probiotic applications. This study supplements the initial safety assessment work already carried out for ZY-312, and contributes to the development of the first probiotic representative from the dominant Bacteroidetes phylum.
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###### 

**(A)** Colonies of ZY-312 on tryptone soy agar (5% sheep blood) following culture in 5% CO~2~ **(A-A)**, air **(A-B)**, or anaerobically **(A-C)** for 48 h at 37°C. **(B)** Cells observed under light microscope following Gram staining (4000×). **(C)** Cells observed under scanning electron microscope (5000×).
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Click here for additional data file.

###### 

**Confirmation of no microbial contamination. (A)** *Escherichia coli* and ZY-312 cultured on Eosin methylene blue agar for 24 h at 37°C. **(B)** *Salmonella enterica* serovar Paratyphi B and ZY-312 cultured on SS agar for 24 h at 37°C. **(C)** *Clostridium sporogenes* and ZY-312 cultured anaerobically on Columbia agar containing blood and gentamicin for 48 h at 37°C. **(D)** *Staphylococcus aureus* and ZY-312 cultured on mannitol sodium chloride agar for 24 h at 37°C. **(E)** *Pseudomonas aeruginosa* and ZY-312 cultured on NAC agar for 24 h at 37°C. **(F)** *Candida albicans* and ZY-312 cultured on Sabouraud dextrose agar for 72 h at 28°C. **(G)** *S. aureus* and ZY-312 cultured on agar agar for 48 h at 37°C. **(H)** *C. albicans* and ZY-312 cultured on rose bengal agar for 96 h at 28°C.
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###### 

**The major fatty acids of ZY-312 as identified by gas chromatography**.
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###### 

**Acute toxicity of ZY-312 to mice. Changes in body weight (%) per day were observed for the experimental and control groups. (A)** Specific pathogen-free (SPF) BALB/c normal mice (*n* = 5) were treated with ZY-312 at a concentration of 1 × 10^9^ cfu/day for 5 days and observed for 15 days. The control group mice were treated with saline. **(B)** SPF normal mice (*n* = 5) were treated with ZY-312 at a concentration of 5 × 10^10^ cfu/day for 5 days and observed for 18 days. Tryptic soy broth was used to treat the control group. No significant weight loss was observed in any of the animals (mean ± SE; NS, not significant, *t*-test).
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###### 

**Phylogenetic tree based on complete shotgun sequences showing the relationship between *Bacteroides fragilis* ZY-312 and closely related species.** The tree was constructed using the neighbor-joining method.
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###### 

**Phylogenetic tree based on complete genome sequences showing the relationship between *B. fragilis* strain ZY-312, *B. fragilis* NCTC 9343, *B. fragilis* YCH46, and *B. fragilis* 638R.** The tree was constructed using the neighbor-joining method.
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